Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: Efficacy and safety in a routine setting

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4771-4777

  Cicone, Francesco ^a   Baldini, Rossella ^a   Cox, Maria Christina ^a   Russo, Eleonora ^b   Torelli, Fabio ^b   Tofani, Anna ^a   Scopinaro, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aggressive lymphoma; Ibritumomab tiuxetan; Indolent lymphoma; Non Hodgkin's lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; PURINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 75149145962     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Molina A: A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Ann Rev Med 59: 237-250, 2008.
2. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P and White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463,2002.
3. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA: Treatment with ibritumomab tiuxetan radioimmuno-therapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269, 2002.
4. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ and Coleman M: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23: 7565-7573, 2005.
5. Davies AJ: Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 26: 3614-3628, 2007.
6. 131I-tositumomab in clinical practice. J Nucl Med 48: 1767-1776, 2007.
7. Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, Lassmann M, Oyen W and Brans B: EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin®). Eur J Nucl Med MoI Imaging 34: 616-622, 2007.
8. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K and Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109: 1804-1810, 2007.
9. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R and Knox SJ: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10: 7792-7798, 2004.
10. Ivanov A, Krysov S, Cragg MS and Illidge T: Radiation therapy with tositumomab (Bl) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 14: 4925-4934, 2008.
11. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J and Multani PS: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2: 1263-1270, 2003.
12. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K and Molina A: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25: 4285-4292, 2007.
13. Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I and Molina A: Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 22: 684-691,2007.
14. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F and Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med 333: 1540-1545, 1995.
15. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J and Marcus R: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110: 54-58, 2007.
16. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, D'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J and Hagenbeek A: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26: 5156-5164, 2008.
17. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, Perrotti A, Fina M, Derenzini E and Baccarani M: A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, non-follicular, non-Hodgkin lymphoma. Cancer 112: 856-862, 2008.
18. Chatal JF, Kraeber-Bodéré F and Barbet J: Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure? Eur J Nucl Med Moi Imaging 35: 1236-1239, 2008.
19. 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14: 7088-7094, 2008.
20. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA and Cheson BD: Use of positron-emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578,2007.
21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M and Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007.
22. Cicone F, Scopinaro F, Baechler S, Ketterer N, Buchegger F, Cox MC, Allenbach G, Tofani A and Bischof Delaloye A: Efficacy of yttrium-90 Zevalin® outside of clinical trials: Preliminary results of a retrospective bi-center study. Blood Supplement (ASH Annual Meeting Abstracts) 112: Abstract ç5015, 2008.
23. Peyrade F,Triby C, Slama B, Fontana X, Gressin R, Broglia JM, Lepeu G, Carrier P, Peyrottes I, Darcourt J, Bondiau PY and Thyss A: Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. Leuk Lymphoma 49:1762-1768,2008.
24. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN and Nademanee A: Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Curr Stem Cell Res Ther 2: 239-248, 2007.